and/or melanoma-associated antigen gp100 were transfected into mouse bone marrow-derived DC, which were used as vaccines in B16 melanoma model.
Introduction
The design of cancer vaccine with potent immunogenicity is an attractive strategy to cancer therapy. 1, 2 Dendritic cells (DC) are the most potent antigen-presenting cells (APC) for the initiation of antigen-specific immune responses. 3 In addition to their ability to efficiently acquire and process antigens, DC express high levels of MHC class I and class II molecules, as well as costimulatory molecules, which are essential to antigen presentation and T cell activation. 4 Thus, they play a crucial role in the initiation of antitumor immune response. Based on these features and development of the methods for expansion of DC on a large scale from hematopoietic precursors, 5 DC have attracted great attention as the vehicles for the delivery of cancer vaccines. Genetic modification of DC to express tumor-associated antigen (TAA) has been documented to be efficacious to induce antitumor immunity in many animal models 6, 7 and partial clinical trials. 8, 9 Transfection of DC with an entire TAA gene has
ance to tumor challenge most effectively. It was found that the tumor mass of mice vaccinated by Lptn/gp100-DC showed obvious necrosis and inflammatory cell infiltration. In vivo depletion analysis demonstrated that CD8 + T cells are the predominant T cell subset responsible for the antitumor effect of Lptn/gp100-DC and CD4 + T cells were necessary in the induction phase of tumor rejection, while NK cells were less important although they participated in the antitumor response either in the induction phase or in the effector phase. In the murine model with the pre-established subcutaneous B16 melanoma, immunization with Lptn/gp100-DC inhibited the tumor growth most significantly when compared with other counterparts. These findings provide a potential strategy to improve the efficacy of DC-based tumor vaccines.
Gene Therapy (2002) 9, 592-601. DOI: 10.1038/sj/gt/3301694 several advantages. First, DC may process and present TAA physiologically to T cells and the CTL generation may be more likely to recognize the naturally processed antigenic epitopes. Second, TAA gene-modified DC can be armed with the full antigenic determinants spectrum of tumor cells. They may also present MHC II-restricted epitopes to CD4 + T cells. Lastly, DC can express tumor antigens continuously and MHC-peptide complexes for long periods. 6, 10 Nevertheless, the antitumor immunity induced by TAA gene-modified DC vaccine is still limited in clinical trials, 11, 12 suggesting that DC-based vaccine will need to be modified to improve the efficacy before being widely used. So, the primary aim of our present study is to enhance the therapeutic efficacy of DC-based vaccine by genetic modification of DC.
In general, DC capture antigen in the periphery and then migrate to T cell areas in lymphoid organs to prime the immune response. 13, 14 The precise molecular mechanisms about DC migration and interactions between DC and T cells are not yet well defined. However, it is becoming increasingly more evident that chemokines play an important role in the migration and recruitment of immune cells including DC and T cells in vivo. 15, 16 Lymphotactin (Lptn) is a C chemokine that specifically regulates the migration of T cells and NK cells. [17] [18] [19] [20] Dilloo et al 21 reported that cotransfection of Lptn and interleukin-2 (IL-2) genes into tumor tissue could induce potent antitumor immunity through an attraction-expansion approach. We have also found that Lptn gene-modified DC could deliver MHC I-restricted tumor antigen peptide more efficiently to induce antitumor immunity in the 3LL Lewis lung carcinoma model. 22 We hypothesized that more potent chemotaxis of antigen-expressing DC on T cells by genetically cotransfected DC with Lptn and TAA might be capable of facilitating the in vivo stimulation of T cells by DC, and consequently favoring DC Ag presentation and T cell activation. Vaccination with DC cotransfected with Lptn and TAA may elicit more significant antitumor effects than the use of TAA genemodified DC alone. So, in this study, we investigated whether vaccination with DC cotransfected with Lptn and melanoma antigen gp100 could induce protective and therapeutic antitumor response more effectively in a B16 melanoma tumor model.
Results
Ad-mediated Lptn and/or gp100 genetic modification of DC Bone marrow-derived DC from C57BL/6 mice were expanded in vitro for 9 days, followed by characterization using composite criteria of typical morphology, cell surface markers and MLR. Surface phenotype analysis by flow cytometry showed that DC expressed high levels of MHC-I, MHC-II, CD40 and CD80 and moderate levels of DC-specific Ag DEC205 (data not shown). MLR revealed that DC were potent stimulators in allogenic MLR (data not shown). The genetic modification of DC was mediated by adenovirus (Ad) vector. Using LacZ as a reporter gene, we evaluated the DC gene transfer efficiency mediated by Ad vector. Twenty-four hours after infection of DC with recombinant Ad encoding LacZ (AdLacZ) at a multiplicity of infection of 100, X-gal staining showed that gene transfer efficiency was >90% (data not shown), which confirmed that Ad vector could efficiently mediate gene transfer into DC. Chemotaxis assay revealed that the culture supernatants from DC, DC transfected with AdLacZ (LacZ-DC) or DC transfected with gp100 (gp100-DC) had no significant chemotactic activity on murine T cells, but the 24 h culture supernatants from DC transfected with Lptn (Lptn-DC) or DC cotransfected with Lptn and gp100 (Lptn/gp100-DC) could attract T cells markedly. This indicates that AdLptn vector can mediate the expression of bioactive Lptn in DC.
Lptn and/or gp100 expressions in Lptn-DC, gp100-DC and Lptn/gp100-DC were further confirmed by RT-PCR. As shown in Figure 1 , neither DC nor LacZ-DC expressed any detectable Lptn or gp100, whereas Lptn mRNA or gp100 mRNA was detected 4 h after genetic modification of DC with AdLptn or Adgp100, respectively, and both Lptn and gp100 mRNAs were detected in Lptn/gp100-DC. In addition, replication-defective Ad vector transfection did not affect the DC phenotype obviously except for a high level of gp100 expression, which was detected on the surface of gp100-DC and Lptn/gp100-DC by FACS (data not shown).
We investigated the capacity of gene-modified DC to prime naive syngeneic T cells in vitro, as measured by an antigen-specific proliferative response. The splenic T cells from C57BL/6 mice were stimulated in vitro with syngeneic untransfected DC or DC transfected with Ad vectors expressing various genes. As shown in Figure 2 , DC transfected with Ad vectors encoding various genes were found to induce proliferation of naive syngeneic T lymphocytes, most likely due to processing and presentation of transgene products and/or Ad proteins by DC. DC cotransfected with Lptn and gp100 could induce T cell proliferation most significantly (P Ͻ 0.01). Figure 3a demonstrated that gp100-DC immunization alone showed a marked inhibitory effect on tumor growth when compared with Lptn-DC, LacZ-DC, DC or PBS control groups (P Ͻ 0.01). The inhibition of melanoma growth could be observed most significantly in mice after vaccination with Lptn/gp100-DC when compared with that in mice vaccinated by gp100-DC, Lptn-DC, LacZ-DC, DC or PBS (P Ͻ 0.01). The majority (75%) of the mice immunized with Lptn/gp100-DC remained tumor-free 90 days after B16 cells challenge, and only 12.5% of the mice immunized with gp100-DC were tumor free, whereas the mice immunized with PBS, DC, LacZ-DC or Lptn-DC counterparts showed no significant protection against the inoculated B16 cells in three independent experiments. Eight mice in each group were observed for their survival period. Figure 3c shows that the mice immunized with gp100-DC alone survived much longer than the mice immunized with Lptn-DC, LacZ-DC, DC or PBS (P Ͻ 0.01), and the survival period was further prolonged in mice immunized with Lptn/gp100-DC as compared with that of mice in other groups (P Ͻ 0.01). However, if the vaccinated mice were challenged with the irrelevant EL-4 lymphoma cells, no protective effect could be observed in mice vaccinated by Lptn/gp100-DC, as well as in mice of other groups (Figure 3b and d) . These results showed that vaccination with gp100-DC alone could provide protection against B16 tumor challenge, but less effectively than vaccination with Lptn/gp100-DC. It suggested that Lptn and gp100 cotransfected DC could elicit protective, specific antitumor immunity more potently. 
B16 melanoma cells or control EL-4 cells. Tumor size was monitored with calibers every other day and calculated as the product of maximal perpendicular diameters (a and b). Eight mice in each group were observed for their survival time (c and d).

More potent specific CTL cytotoxicity induced by immunization of DC cotransfected with Lptn and gp100
The splenocytes derived from mice of various groups were restimulated in vitro with inactivated B16 or EL-4 (transfected with or without Adgp100) tumor cells for CTL induction. Consistent with the protection against the challenge of B16 melanoma cells, the mice immunized with gp100-DC exhibited a B16 melanoma-specific CTL response which was higher than that of mice immunized with Lptn-DC, LacZ-DC or DC (P Ͻ 0.01), but it was less potent than that induced by immunization with Lptn/gp100-DC (P Ͻ 0.01). The highest CTL activity against B16 cells was induced in mice immunized with Lptn/gp100-DC when compared with that in mice of other groups (Figure 4a ). Figure 4b showed that no significant cytotoxicity on syngeneic EL-4 T-lymphoma cells was found with these induced lymphocytes. However, specific cytotoxic T lymphocytes could recognize and kill EL-4 cells transfected with Adgp100 (Figure 4c ), but not EL-4 cells transfected with AdLacZ (data not shown). It suggested that gp100-specific immunity was induced most significantly by immunization of DC cotransfected with Lptn and gp100.
Increased NK activity after immunization of DC cotransfected with Lptn and gp100
One week after immunization of normal mice with various vaccines, the splenocytes were used in cytolytic assay against YAC-1 cells at effector:target (E:T) ratios at 20:1, 40:1 and 80:1. As shown in Figure 5 , NK activity in mice immunized with gp100-DC or Lptn-DC alone increased when compared with those in mice vaccinated with LacZ-DC, DC or PBS (P Ͻ 0.05), while the splenic NK activity increased most significantly after immunization with Lptn/gp100-DC when compared with that after Gene Therapy immunization with other vaccines (P Ͻ 0.01). These data suggested that the enhancement of nonspecific immunity might also be involved in the antitumor response of the Lptn/gp100-DC immunization.
Enhanced Th1 type cytokine production after immunization of DC cotransfected with Lptn and gp100
Seven days after a single vaccination of DC, LacZ-DC, Lptn-DC, gp100-DC or Lptn/gp100-DC, we determined the production of IL-2 and IFN-␥ by splenocytes stimulated in vitro with inactivated B16 cells at a 10:1 ratio in a total volume of 1 ml at 37°C, 5% CO 2 for 48 h. The data in Figure 6 showed that splenocytes from mice immunized with gp100-DC produced significantly higher levels of IL-2 and IFN-␥ than those from mice immunized with Lptn-DC, LacZ-DC, DC or PBS (P Ͻ 0.01). The splenocytes from mice immunized with DC cotransfected with Lptn and gp100 secrected the highest levels of IL-2 and IFN-␥ as compared with those from mice after other vaccinations.
More massive infiltration of inflammatory cells into the tumor mass after immunization of DC cotransfected with Lptn and gp100
Subcutaneous tumor nodules were taken from tumorbearing mice that had been killed 3 weeks after tumor challenge. Histological examination of tumor mass showed that the most obvious tumor necrosis and infiltration of inflammatory cells (neutrophils, lymphocytes, monocytes) was present inside and around the tumors of the tumor-bearing mice immunized with Lptn/gp100-DC. Inflammatory cell infiltration was markedly observed in mice immunized with gp100-DC, whereas relatively less infiltration was present in the tumors of Lptn-DC immunized mice. However, little infiltration of inflammatory cells was found inside and around tumors of PBS, DC and LacZ-DC control groups (Table 1 ). 
a Tumor necrosis: Ϫ, no necrosis; +, less than 1/3 of the tumor size; ++, between 1/3 and 2/3 of tumor size; +++, more than 2/3 of the tumor size. b The infiltration of inflammatory cells both in and around the tumor was evaluated as following: Ϫ, no inflammatory cell infiltration; +, minimal inflammatory cell infiltration; ++, medium inflammatory cell infiltration; +++, intense inflammatory cell infiltration.
The roles of T cells and NK cells in the induction of antitumor immunity by DC cotransfected with Lptn and gp100
To investigate the responsibility of T cell subpopulations and NK cells in the protective immunity induced by the Lptn/gp100-DC vaccine, the mice were depleted of CD4 + T cells, CD8 + T cells, or NK cells during immunization or during tumor challenge. As shown in Figure 7a and b, depletion of CD8 + T cells during immunization or during tumor challenge abrogated the protective immunity induced by Lptn/gp100-DC. Mice depleted of CD4 + T cells during immunization failed to reject tumor challenge. However, the mice could resist tumor challenge when CD4
+ T cells were depleted during tumor challenge. These data confirmed that CD8 + T cells were the predominant effector cells in antitumor immunity and that CD4 + T cells were required for the induction of CD8 + -dependent T cell immunity, but were unnecessary in the effector phase. Mice depleted of NK cells during immunization or during tumor challenge showed slightly larger tumors than mice in the control group, but much smaller than the mice depleted of CD8 + T cells (P Ͻ 0.01), indicating that NK cells also participated in the antitumor immunity, but were less important than T cells.
More effective induction of therapeutic antitumor immunity by immunization of DC cotransfected with Lptn and gp100
The experiments described above illustrated that the Lptn/gp100-DC vaccine could result in the induction of the cell-mediated immune response that is capable of protecting mice from a subsequent tumor challenge. To evaluate this vaccination strategy in a model that is more analogous to the clinical setting, the therapeutic effect of Lptn/gp100-DC therapy was tested in the pre-established tumor-bearing mice. Mice were inoculated s.c with 2 × 10 5 B16 tumor cells in a back limb. Three days later, the tumor-bearing mice were injected s.c. into two sides of the flank region with DC vaccines (one of the following groups: PBS, DC, LacZ-DC, Lptn-DC, gp100-DC, Lptn/gp100-DC). The same vaccination was repeated after another week. As shown in Figure 8a , 20 days later, the mean tumor diameter of mice in the PBS, DC, LacZ- The results showed that vaccination with gp100-DC could inhibit the tumor growth when compared with Lptn-DC, LacZ-DC, DC or PBS, but less effective than the Lptn/gp100-DC vaccine. The most significant suppression of tumor growth could be observed in the mice treated with Lptn/gp100-DC when compared with that of other groups (P Ͻ 0.01).
The therapeutic effect of Lptn/gp100-DC vaccine on the established tumors was further confirmed by evaluating the survival of the tumor-bearing mice. As shown in Figure 8b , treatment with gp100-DC alone could extend animal survival, but was less effective than the treatment with Lptn/gp100-DC (P Ͻ 0.01). Lptn-DC, lacZ-DC or DC administration did not exhibit significant extending effects on the survival of the tumor-bearing mice, as well as PBS control group. These results suggested that Lptn/gp100-DC vaccine could induce therapeutic antitumor immunity more potently.
Discussion
The identification of TAA recognized by specific immune cells of cancer patients has opened new strategies for the development of antigen-specific vaccines. 24, 25 Vaccination 
B16 melanoma cells, 3 days later mice (n = 6 per group) were immunized s.c. twice with PBS, DC, LacZ-DC, Lptn-DC, gp100-DC, Lptn/gp100-DC at weekly interval. DC were administered at a dose of 1 × 10 5 . Tumor measurements were made 20 days after tumor challenge (a). The heights of columns represent mean tumor diameters. Survival period of melanomabearing mice after vaccination with Lptn/gp100-DC (b). Survival was recorded as the percentage of surviving animals. Mice becoming moribund were killed. Data are representative of three independent experiments.
with DC transferred with TAA gene offers the advantage of presenting multiple epitopes in the context of MHC class I and class II molecules, 6 and it seems to be an attractive approach for cancer immunotherapy. Different viral vectors, including retroviral vector, 26 Ad vector, 27 and vaccinia vector, 28, 29 have been evaluated to genetically modify DC. Among them, Ad vector was confirmed to be a good candidate because of its high efficiency and minimum risk associated with insertional mutagenesis. 7, 27, 30 However, the antitumor effects of immunization with DC genetically modified with TAA gene alone are still far from satisfactory. The reasons may be manifold and partly due to the failure to recruit lymphocytes of the appropriate specificity. Chemokines are a superfamily of polypeptides and parts of them can migrate T, NK cells, DC or macrophages, then boost the antitumor immune response. 31, 32 Many studies have demonstrated that gene transfer with a variety of chemokines elicits potent antitumor activity. Lptn and RANTES gene transfer could generate antitumor immunity and inhibit the tumor growth. 33, 34 IP-10 and MIG are potent chemoattractants for Th1 and induce T lymphocytes to the tumor site and result in tumor regression. 35 Injection of adenovirus-mediated encoding MIP-3␣ into subcutaneous tumors induced the local accumulation of DC and elicited tumor-specific CTL activity, and significantly inhibited growth of established tumors. 36 Recent findings have demonstrated that SLC could also induce potent antitumor response and inhibited the tumor growth in a CD8
+ T cell-dependent manner. 37 Gene Therapy
Lptn is a unique member of the C class of chemokines. Ex vivo experiments have suggested that the Lptn is particularly important for the recruitment of T cells and NK cells to the site of an immune response. [17] [18] [19] [20] Therefore, the cotransfection of Lptn and TAA gene into DC may have the potential to overcome the above limitation and may be a promising approach to improve the therapeutic efficacy of DC-based tumor vaccines. Many studies showed that DC could attract T cells by secreting chemokines. 38, 39 Our previous study demonstrated that Lptn-DC exhibited enhanced preferential chemotaxis to T cells, and were capable of delivering tumor antigen peptide more efficiently to induce tumor rejection in 3LL Lewis lung carcinoma models. 22, 40 Certain human cancers have been found to express TAAs that can be recognized immunologically, such as melanoma antigens, polymorphic epithelial mucin (PEM), HER2/neu protooncogen and so on. 2, 41 One such antigen is the gp100 glycoprotein, which is expressed on most human melanoma cells and can effectively induce a CTL response. 6, 7, 42 In this study, we selected the human gp100 glycoprotein (80% homology protein sequence to murine gp100) as a target TAA, because it can induce much more effective immune response than murine gp100 in mouse models. 27, 43 Our results demonstrated that Lptn gene cotransfection into DC could enhance the therapeutic efficacy of DC-based gp100 vaccine without detrimental changes of DC phenotype. Transfected DC were also functionally active in vitro as assessed by their ability to induce primary proliferation of syngeneic T lymphocytes. In vivo testing showed that inhibition of tumor growth by vaccination with Lptn/gp100-DC was observed most significantly either in a pre-immunization model or in a therapeutic setting when compared with that in mice immunized with gp100-DC alone. Consistent with the previous study, 21 although Lptn-DC could recruit T lymphocytes and NK cells, we found that the Lptn-DC vaccine had little protective and therapeutic effect in vivo. The reason may be associated with the role of NK cells being limited when insufficient T cells were activated, because the receptor of Lptn is not expressed on naive T cells, 44 which suggests that the effect of Lptn gene expression depends on the presence of already activated T cells.
The mechanisms involved in the improved antitumor efficacy of the Lptn/gp100-DC vaccine might be related to the following aspects. First, effective induction of cellmediated immune response after Lptn/gp100-DC immunization might play an important role. The splenic NK and CTL cytotoxicities were enhanced significantly after immunization with Lptn/gp100-DC vaccine. It suggested that the non-specific and specific antitumor immunity were activated potently and might be involved in the antitumor response of Lptn/gp100-DC vaccine. In vivo depletion experiments with anti-NK1.1, anti-CD4 and anti-CD8 monoclonal antibodies illustrated that CD8 + T cells were the predominant effector cells and CD4 + T cells were required for the induction of CD8 + -dependent T cell immunity, but were unnecessary in the effector phase, and NK cells were also concerned with the antitumor effect but were less important. These results suggested that priming of CTLs and induction of effective antitumor immunity by gene-modified DC required the presentation of MHC class II-restricted epitopes to CD4 + T cells, which agreed with the previous report that expression of the complete TAA by DC allowed the synchronous presentation of multiple epitopes to T cells. 6, 10 Our data demonstrated that Lptn/gp100-DC vaccine could activate CD4 + and CD8 + T cell-mediated immune responses, and interaction with T cells undertook a major role in the antitumor immunity.
Secondly, Lptn autocrine by DC in the local microenviroment enables DC to attract T and NK cells more efficiently, favors DC Ag presentation, and hence improves the efficacy of DC-based vaccines. Therefore, we cotransfected Lptn gene into DC and expected it to recruit more lymphocytes for the activation of an antitumor immune response. The results of histological examination showed that inflammatory cells were observed most significantly to be present around and in the tumor mass after Lptn/gp100-DC immunization. These results illustrated that the local immune reponse in tumor mass was activated and might contribute to the augmented antitumor efficacy after immunization with DC vaccine cotransfected chemokine and TAA gene. Whether Lptn autocrine by Lptn-DC affects in vivo migration and tissue localization of T and NK cells may be further investigated.
Lastly, it is accepted that the balance between Th1 and Th2 cells plays an important role in antitumor immune response. 45 IL-2 and IFN-␥, produced by Th1 cells and NK cells, are critically important for the induction of antitumor cellular immunity in vivo. 46 So, induction of Th1 type cytokines can be beneficial to tumor eradication. Here, we showed that the production of IL-2 and IFN-␥ from splenocytes increased after the mice immunized with gp100-DC alone, while their levels in mice immunized with Lptn/gp100-DC were the highest when compared with those of other groups. The reason may be related to the fact that more T cells and NK cells were attracted by Lptn from Lptn/gp100-DC, and activated by the DC presenting epitopes. Then, more Th1 cytokines were secreted. Of course, it is possible that exogenous gene modification may affect some aspects of DC biology, including antigen processing, presentation, migration, longevity and so on, which could contribute to the increase in antitumor immunogenicity. This needs further investigation.
Overall, immunization of Lptn and gp100 cotransfected DC could induce protective and therapeutic antitumor immunity more potently. Efficient induction of specific and non-specific antitumor immunity, both locally and systemically, might be responsible for the enhanced efficacy of the cotransfected DC immunization. These observations outline a potent strategy to improve the efficacy of DC-based tumor vaccines.
Materials and methods
Cell lines and animals 293 is a human embryonic kidney cell line transformed with adenovirus type 5 (Ad5) E1A and E1B genes and supporting the propagation of E1-deleted replicationdeficiency adenoviruses. B16 is a melanoma cell line derived from C57BL/6 mice, YAC-1 is an NK-sensitive lymphoma cell line, and EL-4 is a T-lymphoma cell line of C57BL/6 origin. All of the above cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VT, USA). Cells were cultured in RPMI-1640 medium (GIBCO-BRL, Gaithersburg, MD, USA) supplemented with 10% heat-inactivated fetal calf serum (FCS; HyClone, Logan, UT, USA), 2 mM glutamine, penicillin 100 U/ml, and streptomycin 100 g/ml. Female wild-type C57BL/6 mice (H-2K b ), 6-8 weeks old, were purchased from Joint Ventures sipper BK Experimental Animal Company (Shanghai, China) and housed in a specific pathogen-free condition for all experiments.
Preparations of recombinant adenoviruses
The procedure of preparations of the recombinant adenovirus vectors harboring lacZ reporter gene, mouse Lptn and human gp100 cDNA have been described previously. 22 Briefly, lacZ, mouse Lptn or human gp100 cDNA was placed under the control of the cytomegalovirus (CMV) promoter, and their expression cassettes were inserted into the ClaI site of the cosmid vector pAdex1cw (kindly provided by I Saito, Tokyo University, Tokyo, Japan), which bears an Ad5 genome spanning 1-99.3 map units (MU) with deletions of E1A, E1B and E3. The resultant recombinant cosmid was cotransfected into 293 cells with EcoT221-digested Ad5 DNA-terminal peptide complex (DNA-TPC) by calcium phosphate precipitation, and the recombinant adenoviruses were generated by homologous recombinant. The incorporation of expression was confirmed by digestion with appropriate restriction enzymes. The recombinant viruses were propagated in 293 cells and purified on CsCl density gradient, and titers were determined by plaque assay on 293 cells. The adenovirus solutions were stored at -80°C.
Generation of DC from bone marrow
The procedure has been described previously. 22 Briefly, bone marrow cells from C57BL/6 mice were depleted of erythrocytes by addition of ammonium chloride. Cells were plated in six-well culture plates (10 6 cells/ml, 4 ml/well) in RPMI 1640 medium supplemented with 10% heat-inactivated FCS, 50 M 2-ME, 10 mM HEPES (pH 7.4), 2 mM glutamine, penicillin (100 U/ml), streptomycin (100 g/ml), 20 ng/ml recombinant murine GM-CSF (Sigma, St Louis, MO, USA) and 1 ng/ml recombinant murine IL-4 (PeproTech, Rocky Hill, NJ, USA). On day 3 of culture, floating cells were gently removed and fresh medium was added. On day 7 of culture, nonadherent and loosely adherent cells were collected and replated in six-well culture plates (10 6 cells/ml, 4 ml/well). On day 9 of culture, nonadherent cells (DC) were harvested for identification and genetic modification.
Genetic modification of DC
For adenovirus-mediated genetic modification, 1-2 × 10 6 DC were washed twice with PBS and resuspended in 100-200 l of serum-free RPMI 1640 medium with AdLacZ, AdLptn, Adgp100, or AdLptn combined with Adgp100 at a multiplicity of infection (MOI) of 100. After 1 h of incubation at 37°C (with gentle agitation every 20 min), the cells were washed with PBS and resuspended in 1 ml of RPMI 1640 medium supplemented with 10% FCS (1 × 10 6 cells/ml). Twenty-four hours after genetic modification, LacZ-DC were collected for 5-bromo-4-chloro-3-indolyl-␤-D-galacto-pyranoside (X-gal) staining to evaluate gene transfer efficiency, and the culture supernatants from DC or gene-modified DC were harvested for chemotaxis assay as described previously. 22 Briefly, duplicate wells of the lower half of the microchemotaxis chamber (NeutroProbe, Cabin John, MD, USA) were filled with the appropriate dilutions of DC supernatants or standard human Lptn (PharMingen, San Diego, CA, USA), and the upper chambers of the assembly were filled with 40 l of the appropriate cell suspension (2 × 10 6 cells/ml). Murine T cells were isolated from splenocytes of C57BL/6 mice using nylon wool column and the cell purity according to this protocol was routinely more than 85%, which was assessed by FACS analysis. Data were obtained by counting five nonoverlapping high power microscope fields from each well. Cells were considered to be chemoattracted if the chemotactic index (number of cells migrating in experimental well/number of cells migrating in medium only) was >2. In addition, RT-PCR was also performed on gene-modified DC to analyze Lptn and/or gp100 expression. Before PCR amplification, the reverse transcripts were digested with RNase-free DNase to degrade the potentially contaminated DNA templates. The upstream primer of mouse ␤-actin was 5'-TGGAATCCTGTGGCATCCATGAAAC-3', and the downstream primer was 5'-TAAAACGCAGCTCAG-TAACAGTCCG-3', with an expected PCR product of 359 bp. The specific upstream primer for mouse Lptn was 5'-TGGGGACTGAAGTCCTAGAAG-3', and the downstream primer was 5'-TTACCCAGTCAGGGTTA CTGCTGTG-3', with the product size of 300 bp. The specific upstream primer for human gp100 was 5'-GCTTGGTGTCTCAAGGCAACT-3', and the downstream primer was 5'-CTCCAGGTAAGTATGAGTGAC-3', with an expected product size of 750 bp.
Mixed leukocyte reaction (MLR)
Spleen cells from naive C57BL/6 mice were passed over nylon wool and used as responder cells at 2 × 10 5 /well in U-bottom 96-well plates. Syngeneic DC that were untransfected or transfected with AdLacZ, AdLptn and/or Adgp100 were inactivated by 50 g/ml mitomycin for 30 min and added to responder cells in varying cell numbers. Cells were cultured in RPMI 1640 medium containing 10% FCS at 37°C and 5% CO 2 for 5 days. Control wells contained either DC alone or T cells alone. Cell cultures were pulsed with 3 H-thymidine (1 Ci/well) (Amersham, Pharmacia Biotech, Freiburg, Germany) during the last 18 h. Cells were harvested on to glass fiber filters, and 3 H-thymidine uptake was determined by liquid scintillation counting using a microBeta counter (Beckman, Krefeld, Germany). Responses were reported as mean c.p.m. ± s.e.m. from triplicate samples.
Immunization and tumor challenge
The C57BL/6 mice were divided into six groups and were injected s.c. into two sides of flank region with one of the following preparations: PBS, untransfected DC, LacZ-DC, Lptn-DC, gp100-DC and Lptn/gp100-DC (1 × 10 5 cells). Seven days after vaccination with DC, the mice were injected s.c. into a back limb with a dose of 2 × 10 5 B16 cells. To evaluate the specificity of the antitumor immunity induced by DC vaccines, the immunized mice were also challenged with syngenic EL-4 T-lymphoma cells. The length and width of tumor mass were measured with calibers every other day after tumor inoculation. Tumor size was expressed as 1/2 (length + width). Mice were killed when the challenged tumors reached 3 cm in diameter or severe ulceration developed. All
Gene Therapy experiments were performed three times using individual treatment groups of eight mice. Data are representative of three experiments performed.
Immunotherapy of the pre-established B16 melanoma model Three days after subcutaneous inoculation of 2 × 10 5 B16 cells, the tumor-bearing C57BL/6 mice were divided into six groups and vaccinated s.c. twice at weekly intervals with one of the following preparations: PBS, untransfected DC, LacZ-DC, Lptn-DC, gp100-DC and Lptn/gp100-DC (1 × 10 5 cells), each group contained six mice. The length and width of the tumor mass were measured with calibers every other day after tumor inoculation. Tumor size was expressed as 1/2 (length + width). Six mice in each group were observed for their survival period.
Cytotoxic assay of CTL and NK cells
Splenic lymphocytes were isolated from the mice 1 week after vaccination. The erythrocytes were depleted with 0.83% ammonium chloride and macrophages were removed by adherence of splenocytes on plastic plates for 2 h. The non-adherent lymphocytes were directly used as NK effector cells. The lymphocytes were cocultured with inactivated B16, EL-4 or EL-4 transfected with Adgp100 (treated by 50 g/ml mitomycin for 30 min) for 7 days in the presence of 20 U/ml recombinant murine IL-2 (Woburn, CA, USA) and then collected as CTL effector cells. The NK activity and CTL activity were determined by lactate dehydrogenase (LDH) release assay with CytoTox 96 Non-Radioactive Cytotoxicity Assay kit (Promega, Madison, WI, USA). 23 The target cells (YAC-1 cells, B16 cells or EL-4 transfected with or without Adgp100) were washed three times with RPMI 1640 medium containing 5% FCS to remove adherent LDH derived from lysed cells. The cell suspension was diluted with RPMI 1640 medium containing 5% FCS to give final concentration of 1 × 10 5 cells/ml. 100 l target cell suspension and 100 l different ratios of effector cells were pipetted together into the wells of a round-bottomed microtiter plate. Suspensions containing exclusively effector cells, target cells, or culture medium, respectively, served as controls to estimate the LDH background. The plates were incubated for 4 h in a humidified 5% CO 2 atmosphere at 37°C. After incubation, they were centrifuged for 10 min. Then 100 l of the supernatant from each well was transferred to the corresponding well of enzymatic assay plate. 50 l reconstituted substrate mix (containing lactate and NAD + ) was added to each well. The plate was covered and incubated at room temperature (protected from light). Thirty minutes later, 50 l stop solution was added to each well. The reaction was measured in an ELISA reader at a wavelength of 490 nm. Calculations were carried out according to the following formula: % of specific lysis = 100 × (experimental Ϫ effector spontaneous Ϫ target spontaneous)/(target maximum Ϫ target spontaneous).
Cytokine induction and measurement of splenocytes
The non-adherent splenocytes derived from mice killed 7 days after vaccination and the cells were washed three times with PBS. For induction of IL-2, IFN-␥, 5 × 10 6 cells of splenocytes were incubated with inactivated B16 cells (treated by 50 g/ml mitomycin for 30 min) at a 10:1 ratio in a total volume of 1 ml at 37°C, 5% CO 2 for 48 h and then the supernatants were harvested. The cytokines were measured using a standard sandwich ELISA technique with corresponding kits purchased from Endogen (Woburn, CA, USA).
In vivo depletion of immune cell subsets
Mice were immunized once with 1 × 10 5 DC, and challenged with 2 × 10 5 B16 cells 11 days after immunization. Four days before DC vaccination or tumor challenge, the mice started to receive a total of five intraperitoneal injections of asites (0.1 ml per mouse per injection) from hybridoma-bearing mice at intervals of 3 days. The monoclonal antibodies used were GK1.5 anti-CD4, 2.43 anti-CD8, or PK136 anti-NK1.1 (HB 191; ATCC). Normal rat IgG (Sigma, St Louis, MO, USA) was given as mock control. Depletion of T cell subsets and NK cells was monitored by flow cytometry, which showed >90% specific depletion in splenocytes.
Histologic examination
Subcutaneous tumor nodules were taken from tumorbearing mice killed 3 weeks after tumor cells challenge. The tumor samples were fixed in 10% formalin solution, dehydrated and embedded in paraffin. Thin-sliced sections were staining with hematoxylin and eosin. The tumor necrosis was graded as following: Ϫ, no necrosis; +, less than 1/3 of the tumor size; ++, between 1/3 and 2/3 of the tumor size; +++, more than 2/3 of the tumor size. The infiltration of inflammatory cells both in and around the tumor was evaluated as follows: Ϫ, no inflammatory cell infiltration; +, minimal inflammatory cell infiltration; ++, medium inflammatory cell infiltration; +++, intense inflammatory cell infiltration.
Statistical analysis
All the experiments were run in triplicate and the results are means ± s.d. of triplicate determinations (or representative data from one or two independent experiments). Statistical analysis was performed using the Student's t test and log-rank test (for survival analysis). The difference was considered statistically significant when the P value was less than 0.05.
